WO1992013570A3 - Novel complexes containing nucleic acid which can be absorbed into higher eucaryotic cells via endocytosis - Google Patents

Novel complexes containing nucleic acid which can be absorbed into higher eucaryotic cells via endocytosis Download PDF

Info

Publication number
WO1992013570A3
WO1992013570A3 PCT/EP1992/000217 EP9200217W WO9213570A3 WO 1992013570 A3 WO1992013570 A3 WO 1992013570A3 EP 9200217 W EP9200217 W EP 9200217W WO 9213570 A3 WO9213570 A3 WO 9213570A3
Authority
WO
WIPO (PCT)
Prior art keywords
nucleic acid
eucaryotic cells
absorbed
higher eucaryotic
complexes
Prior art date
Application number
PCT/EP1992/000217
Other languages
German (de)
French (fr)
Other versions
WO1992013570A2 (en
Inventor
Max L Birnstiel
Matthew Cotten
Ernst Wagner
Original Assignee
Boehringer Ingelheim Int
Genentech Inc
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Boehringer Ingelheim Int, Genentech Inc filed Critical Boehringer Ingelheim Int
Priority to EP92903641A priority Critical patent/EP0571414B1/en
Priority to DE59207189T priority patent/DE59207189D1/en
Priority to US08/098,265 priority patent/US5922859A/en
Priority to JP4503508A priority patent/JPH06504993A/en
Publication of WO1992013570A2 publication Critical patent/WO1992013570A2/en
Publication of WO1992013570A3 publication Critical patent/WO1992013570A3/en

Links

Classifications

    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K47/00—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient
    • A61K47/50—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates
    • A61K47/51—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates the non-active ingredient being a modifying agent
    • A61K47/68—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates the non-active ingredient being a modifying agent the modifying agent being an antibody, an immunoglobulin or a fragment thereof, e.g. an Fc-fragment
    • A61K47/6835—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates the non-active ingredient being a modifying agent the modifying agent being an antibody, an immunoglobulin or a fragment thereof, e.g. an Fc-fragment the modifying agent being an antibody or an immunoglobulin bearing at least one antigen-binding site
    • A61K47/6883—Polymer-drug antibody conjugates, e.g. mitomycin-dextran-Ab; DNA-polylysine-antibody complex or conjugate used for therapy
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K47/00—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient
    • A61K47/50—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates
    • A61K47/51—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates the non-active ingredient being a modifying agent
    • A61K47/62—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates the non-active ingredient being a modifying agent the modifying agent being a protein, peptide or polyamino acid
    • A61K47/64—Drug-peptide, drug-protein or drug-polyamino acid conjugates, i.e. the modifying agent being a peptide, protein or polyamino acid which is covalently bonded or complexed to a therapeutically active agent
    • A61K47/645—Polycationic or polyanionic oligopeptides, polypeptides or polyamino acids, e.g. polylysine, polyarginine, polyglutamic acid or peptide TAT

Landscapes

  • Health & Medical Sciences (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Engineering & Computer Science (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Animal Behavior & Ethology (AREA)
  • General Health & Medical Sciences (AREA)
  • Chemical & Material Sciences (AREA)
  • Medicinal Chemistry (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Epidemiology (AREA)
  • Veterinary Medicine (AREA)
  • Proteomics, Peptides & Aminoacids (AREA)
  • Public Health (AREA)
  • Molecular Biology (AREA)
  • Biotechnology (AREA)
  • Immunology (AREA)
  • Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
  • Medicinal Preparation (AREA)
  • Preparation Of Compounds By Using Micro-Organisms (AREA)

Abstract

Complexes between internalisation factor-binding factor conjugates and nucleic acid which can be absorbed into higher eucaryotic cells via endocytosis contain, in non-covalently bonded form, one or more substances with an affinity for nucleic acid with the ability to increase the efficiency of the absorption of the complexes into the cell. The non-covalently bonded substance with an affinity for nucleic acid may be the same as the binding factor, and preferably a polycationic substance. The preferred internalisation factor is transferrin. Process for producing the complexes and process for introducing nucleic acid into higher eucaryotic cells. Pharmaceutical preparations containing complexes with a therapeutically active nucleic acid.
PCT/EP1992/000217 1991-02-12 1992-02-01 Novel complexes containing nucleic acid which can be absorbed into higher eucaryotic cells via endocytosis WO1992013570A2 (en)

Priority Applications (4)

Application Number Priority Date Filing Date Title
EP92903641A EP0571414B1 (en) 1991-02-12 1992-02-01 Novel complexes containing nucleic acid which can be absorbed into higher eucaryotic cells via endocytosis
DE59207189T DE59207189D1 (en) 1991-02-12 1992-02-01 NEW COMPLEXES CONTAINED BY ENDOCYTOSIS IN HIGHER EUKARYOTIC CELLS, NUCLEIC ACID
US08/098,265 US5922859A (en) 1992-02-01 1992-02-01 Complexes containing nucleic acid which can be taken-up by endocytosis into higher eukaryotic cells
JP4503508A JPH06504993A (en) 1991-02-12 1992-02-01 Novel nucleic acid-containing complexes that can be taken up by higher eukaryotic cells by endocytosis

Applications Claiming Priority (2)

Application Number Priority Date Filing Date Title
DE4104186A DE4104186A1 (en) 1991-02-12 1991-02-12 NEW COMPLEXES INCLUDING ENDOCYTOSIS IN HIGHER EUKARYOTIC CELLS, NUCLEIC ACID
DEP4104186.0 1991-02-12

Publications (2)

Publication Number Publication Date
WO1992013570A2 WO1992013570A2 (en) 1992-08-20
WO1992013570A3 true WO1992013570A3 (en) 1992-10-29

Family

ID=6424859

Family Applications (1)

Application Number Title Priority Date Filing Date
PCT/EP1992/000217 WO1992013570A2 (en) 1991-02-12 1992-02-01 Novel complexes containing nucleic acid which can be absorbed into higher eucaryotic cells via endocytosis

Country Status (6)

Country Link
EP (1) EP0571414B1 (en)
JP (1) JPH06504993A (en)
AT (1) ATE142890T1 (en)
DE (2) DE4104186A1 (en)
ES (1) ES2094342T3 (en)
WO (1) WO1992013570A2 (en)

Cited By (3)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US8945884B2 (en) 2000-12-11 2015-02-03 Life Technologies Corporation Methods and compositions for synthesis of nucleic acid molecules using multiplerecognition sites
US9358300B2 (en) 1998-11-12 2016-06-07 Life Technologies Corporation Transfection reagents
US9534252B2 (en) 2003-12-01 2017-01-03 Life Technologies Corporation Nucleic acid molecules containing recombination sites and methods of using the same

Families Citing this family (22)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US6022950A (en) * 1984-06-07 2000-02-08 Seragen, Inc. Hybrid molecules having translocation region and cell-binding region
US5977307A (en) * 1989-09-07 1999-11-02 Alkermes, Inc. Transferrin receptor specific ligand-neuropharmaceutical agent fusion proteins
US5672683A (en) * 1989-09-07 1997-09-30 Alkermes, Inc. Transferrin neuropharmaceutical agent fusion protein
US5527527A (en) * 1989-09-07 1996-06-18 Alkermes, Inc. Transferrin receptor specific antibody-neuropharmaceutical agent conjugates
AU675057B2 (en) * 1989-09-07 1997-01-23 Alkermes, Inc. Process for the preparation of transferrin receptor specificantibody-neuropharmaceutical or diagnostic agent conjugates
US5830686A (en) * 1994-01-13 1998-11-03 Calydon Tissue-specific enhancer active in prostate
US6057299A (en) * 1994-01-13 2000-05-02 Calydon, Inc. Tissue-specific enhancer active in prostate
FR2719316B1 (en) * 1994-04-28 1996-05-31 Idm New nucleic acid and polymer complexes, their preparation process and their use for cell transfection.
JPH0889278A (en) * 1994-09-29 1996-04-09 Ajinomoto Co Inc Modified protein for introducing gene and its production
US6015555A (en) * 1995-05-19 2000-01-18 Alkermes, Inc. Transferrin receptor specific antibody-neuropharmaceutical or diagnostic agent conjugates
EP0874910A4 (en) * 1995-06-07 1999-04-21 Life Technologies Inc Peptide-enhanced cationic lipid transfections
US6051429A (en) 1995-06-07 2000-04-18 Life Technologies, Inc. Peptide-enhanced cationic lipid transfections
FR2736642B1 (en) * 1995-07-10 1997-09-12 Pasteur Institut IMMUNOVECTORS, IN PARTICULAR ANTIBODIES AND FRAGMENTS OF ANTIBODIES FOR USE IN THE INTRACELLULAR AND INTRANUCLEAR TRANSPORT OF BIOLOGICALLY ACTIVE PRINCIPLES IN PARTICULAR OF HAPTENES, PROTEINS AND NUCLEIC ACIDS
FR2755976B1 (en) * 1996-11-15 1999-01-15 Idm Immuno Designed Molecules NOVEL COMPLEXES OF NUCLEIC ACIDS AND POLYMER SUBSTITUTED BY RESIDUES CAUSING THE DESTABILIZATION OF CELL MEMBRANES
WO1999006576A1 (en) 1997-08-04 1999-02-11 Calydon, Inc. A human glandular kallikrein enhancer, vectors comprising the enhancer and methods of use thereof
US6927278B1 (en) * 1998-09-01 2005-08-09 Trustees Of The University Of Pennsylvania Peptide scaffolds for transfer of molecules into eukaryotic cells
US6902933B2 (en) * 2000-11-03 2005-06-07 Regents Of The University Of Michigan Surface transfection and expression procedure
WO2004096117A2 (en) * 2003-05-02 2004-11-11 Xpression Antibody Therapeutics, Inc. Drug delivery systems comprising transferrin-nucleic acid conjugates
WO2008073856A2 (en) * 2006-12-08 2008-06-19 Massachusetts Institute Of Technology Delivery of nanoparticles and/or agents to cells
KR102112892B1 (en) 2012-11-15 2020-05-19 로슈 이노베이션 센터 코펜하겐 에이/에스 Oligonucleotide conjugates
EP3142673A4 (en) 2014-05-14 2018-01-03 Targlmmune Therapeutics AG Improved polyethyleneimine polyethyleneglycol vectors
US10195280B2 (en) 2014-07-15 2019-02-05 Life Technologies Corporation Compositions and methods for efficient delivery of molecules to cells

Citations (3)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
EP0387775A1 (en) * 1989-03-16 1990-09-19 BOEHRINGER INGELHEIM INTERNATIONAL GmbH Genetic construct for inhibiting RNA function
EP0388758A1 (en) * 1989-03-16 1990-09-26 BOEHRINGER INGELHEIM INTERNATIONAL GmbH Protein-polycation conjugate
WO1991017773A2 (en) * 1990-05-18 1991-11-28 Boehringer Ingelheim International Gmbh New protein-polycation conjugates

Patent Citations (3)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
EP0387775A1 (en) * 1989-03-16 1990-09-19 BOEHRINGER INGELHEIM INTERNATIONAL GmbH Genetic construct for inhibiting RNA function
EP0388758A1 (en) * 1989-03-16 1990-09-26 BOEHRINGER INGELHEIM INTERNATIONAL GmbH Protein-polycation conjugate
WO1991017773A2 (en) * 1990-05-18 1991-11-28 Boehringer Ingelheim International Gmbh New protein-polycation conjugates

Non-Patent Citations (2)

* Cited by examiner, † Cited by third party
Title
Bioconjugate Chem., Band 2, Nr. 4, Juli/August 1991, American Chemical Society, (Washington, DC, US), E. WAGNER et al.: "DNA-binding transferrin conjugates as functional gene-delivery agents: synthesis by linkage of polylysine or ethidium homodimer to the transferrin carbohydrate moiety", Seiten 226-231, siehe das ganze Dokument (in der Anmeldung erwähnt) *
Proc. Natl. Acad. Sci. USA, Band 87, Mai 1990, (Washington, DC, US), E. WAGNER et al.: "Transferrin-polycation conjugates as carriers for DNA uptake into cells", Seiten 3410-3414, siehe das ganze Dokument *

Cited By (4)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US9358300B2 (en) 1998-11-12 2016-06-07 Life Technologies Corporation Transfection reagents
US9309520B2 (en) 2000-08-21 2016-04-12 Life Technologies Corporation Methods and compositions for synthesis of nucleic acid molecules using multiple recognition sites
US8945884B2 (en) 2000-12-11 2015-02-03 Life Technologies Corporation Methods and compositions for synthesis of nucleic acid molecules using multiplerecognition sites
US9534252B2 (en) 2003-12-01 2017-01-03 Life Technologies Corporation Nucleic acid molecules containing recombination sites and methods of using the same

Also Published As

Publication number Publication date
ES2094342T3 (en) 1997-01-16
DE59207189D1 (en) 1996-10-24
EP0571414B1 (en) 1996-09-18
ATE142890T1 (en) 1996-10-15
WO1992013570A2 (en) 1992-08-20
EP0571414A1 (en) 1993-12-01
JPH06504993A (en) 1994-06-09
DE4104186A1 (en) 1992-08-13

Similar Documents

Publication Publication Date Title
WO1992013570A3 (en) Novel complexes containing nucleic acid which can be absorbed into higher eucaryotic cells via endocytosis
AU2593292A (en) New conjugates for the introduction of nucleic acid into higher eukaryotic cells
EP0294703A3 (en) Bifunctional antibody constructs and method for selectively destroying cell populations
WO1997025070A3 (en) Lipophilic peptides for macromolecule delivery
AU3196795A (en) Linked peptide nucleic acids
AU1212588A (en) Improvements in and relating to packaging
ES2112982T3 (en) COMPOSITION RELATING TO A DIETARY DRINK.
GR3018029T3 (en) New protein-polycation conjugates.
CA2298659A1 (en) Fast-acting analgesic
IL105503A0 (en) Active compounds
CA2351620A1 (en) Nano-emulsion of 5-aminolevulinic acid
DK154537C (en) QUICK-DISINTEGRATING COMPRESSED PHARMACEUTICAL PREPARATIONS
AU586237B2 (en) Non dusty blends of meals or flours with active principles for use in fodder production
EP0217992A3 (en) Lysing or blocking unwanted cells
GR3036634T3 (en) Novel protein polycation conjugates.
CA2183755A1 (en) Pharmaceutical preparation containing plasminogen activators
AU2346388A (en) Improvements brought to solid catalysts in grain form, process for the preparation of these catalysts and applications for the latter
CA2227241A1 (en) Method of decreasing radiation or radio-mimetic chemotherapy for hematopoietic pluripotent cell engraftment
CA2175628A1 (en) Production of recombinant factor viii in the presence of liposome-like substances of mixed composition
AU586988B2 (en) Solid drug formulations and stable suspensions
WO1992019281A3 (en) New conjugates, consisting of a glycoprotein and a nucleic acid-binding substance
ZA88990B (en) A process for the inactivation of viruses having envelopes in protein preparations prepared in vitro with the aid of a cell
IL75228A (en) Conjugates in which certain nonovalent carboxylic ionophores are covalently bonded to a macromolecule,their preparation and pharmaceutical compositions containing them as immunotoxin potentiators
AU5358094A (en) Water-soluble, instant tea product
Rubezhnyak et al. On some peculiarities of uptake of super (14) C-metabolites of Botrytis cinerea by the cells of Chlorella vulgaris 62

Legal Events

Date Code Title Description
AK Designated states

Kind code of ref document: A2

Designated state(s): JP US

AL Designated countries for regional patents

Kind code of ref document: A2

Designated state(s): AT BE CH DE DK ES FR GB GR IT LU MC NL SE

AK Designated states

Kind code of ref document: A3

Designated state(s): JP US

AL Designated countries for regional patents

Kind code of ref document: A3

Designated state(s): AT BE CH DE DK ES FR GB GR IT LU MC NL SE

DFPE Request for preliminary examination filed prior to expiration of 19th month from priority date (pct application filed before 20040101)
WWE Wipo information: entry into national phase

Ref document number: 1992903641

Country of ref document: EP

WWE Wipo information: entry into national phase

Ref document number: 08098265

Country of ref document: US

WWP Wipo information: published in national office

Ref document number: 1992903641

Country of ref document: EP

WWG Wipo information: grant in national office

Ref document number: 1992903641

Country of ref document: EP